Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression
Open Access
- 11 December 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 1724
Abstract
Leprosy remains a health problem in several countries. Current management of patients with leprosy is complex and requires multi-drug therapy. Nonetheless, antibiotic treatment is insufficient to prevent nerve disabilities and control Mycobacterium leprae. Successful infectious disease treatment demands an understanding of the host immune response against a pathogen. Immune-based therapy is an effective treatment option for malignancies and infectious diseases. A promising therapeutic approach to improve the clinical outcome of malignancies is the blockade of immune checkpoints. Immune checkpoints refer to a wide range of inhibitory or regulatory pathways that are critical for maintaining self-tolerance and modulating the immune response. Programmed cell death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and lymphocyte-activation gene-3 (LAG-3) are the most important immune checkpoint molecules. Several pathogens, including M. leprae, are supposed to utilize these mechanisms to evade the host immune response. Regulatory T cells and expression of co-inhibitory molecules on lymphocytes induce specific T-cell anergy/exhaustion, leading to disseminated and progressive disease. From this perspective, we outline how the co-inhibitory molecules PD-1, PD-L1, and Th1/Th17 versus Th2/Treg cells are balanced, how antigen-presenting cell maturation acts at different levels to inhibit T cells and modulate the development of leprosy, and how new interventions interfere with leprosy development.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2010/18142-8)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (441762/2014-0)
This publication has 81 references indexed in Scilit:
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infectionNature Immunology, 2011
- Regulation of Trypanosoma cruzi-Induced Myocarditis by Programmed Death Cell Receptor 1Infection and Immunity, 2011
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenanceProceedings of the National Academy of Sciences, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Divergence of Macrophage Phagocytic and Antimicrobial Programs in LeprosyCell Host & Microbe, 2009
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesJournal of Experimental Medicine, 2009
- Identification of a human CD8+regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4Proceedings of the National Academy of Sciences, 2007
- The Continuing Challenges of LeprosyClinical Microbiology Reviews, 2006